肾脏病与心力衰竭:近期进展与当前挑战——KDIGO争议会议结论
心力衰竭与慢性肾脏病常共存,增加住院、疾病进展和死亡风险。2024年3月KDIGO争议会议探讨两者双向关系、生物标志物解读及SGLT2抑制剂、RAAS抑制剂、finerenone和GLP-1受体激动剂等治疗获益与证据局限,强调启动指南导向心衰治疗后肾功能小幅下降通常无需停药,并呼吁整合管理及CKD特异性心衰诊断阈值。
要点
- 心衰与CKD常共存且互为风险,需整合管理。
- SGLT2i、RAASi、finerenone和GLP-1RA对心衰和CKD均有获益。
- 启动指南导向心衰治疗后肾功能小幅下降常为血流动力学性,无需停药。
核心结论
- 心衰与CKD存在复杂双向关系,需基于个体化、临床背景和共同治疗目标的整合管理。
研究设计与样本
- 2024年3月KDIGO召开争议会议,讨论肾脏病与心力衰竭的近期进展与当前挑战。
主要发现
- 心衰与CKD常共存,增加住院、疾病进展和死亡风险。
- 两者共享危险因素和重叠病理生理,生物标志物如利钠肽和血肌酐解读存在细微差别。
- SGLT2抑制剂、RAAS抑制剂、finerenone和GLP-1受体激动剂对心衰和CKD患者均有获益,但晚期CKD证据有限。
- 启动指南导向心衰治疗后肾功能小幅下降常为血流动力学性,与不良结局无关,通常无需停药。
关键数值与推荐
- 会议强调需要CKD特异性心衰诊断阈值和心衰中急性肾损伤的细化定义。
- 未来心血管和肾脏试验应纳入肾功能轨迹、症状负担和生活质量等相关终点。
临床怎么用
- 启动指南导向心衰治疗后肾功能小幅下降通常无需停药。
- 对心衰合并CKD患者采用整合管理,注重个体化、临床背景和共同治疗目标。
局限性
- 晚期CKD中心衰和CKD治疗药物的证据仍然有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, which elevates the risks of hospitalization, disease progression, and death. Despite advances in treating each condition independently, many challenges remain in diagnosing and managing them in combination. In March 2024, Kidney Disease: Improving Global Outcomes (KDIGO) held the Controversies Conference on Kidney Disease and Heart Failure: Recent Advances and Current Challenges. Discussions highlighted the complex, bidirectional relationship between HF and CKD, including shared risk factors and overlapping pathophysiology as well as nuances in interpreting biomarkers such as natriuretic peptides and serum creatinine. Sodium-glucose cotransporter-2 inhibitors, renin-angiotensin-aldosterone system inhibitors, and emerging agents such as finerenone and glucagon-like peptide-1 receptor agonists can have benefits in both populations of patients with HF and CKD, though evidence in advanced CKD remains limited. Importantly, small declines in kidney function after initiating guideline-directed HF therapies generally do not require discontinuation, as these declines are often hemodynamic in nature and not associated with poor outcomes. The group highlighted the need for CKD-specific HF diagnostic thresholds and refined acute kidney injury definitions in HF. It is important for future cardiovascular and kidney trials to include relevant end points, such as kidney function trajectories, symptom burden, and quality of life. To improve care for individuals with HF and CKD, a more integrated approach to management, rooted in individualization, clinical context, and shared therapeutic goals, is needed.
引用
- Lam CSP, Bozkurt B, Cherney DZI, et al. Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2026. PMID: 41791738. doi:10.1016/j.kint.2025.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。